Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2024-08-07 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
港股公告：百济神州有限公司截至2024年6月30日止三个月及六个月未经审核业绩以及业务进展最新情况
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from BeiGene, Ltd. regarding its unaudited financial results for the three and six months ended June 30, 2024. It includes comprehensive financial data such as revenue, operating expenses, GAAP and non-GAAP results, earnings per share, and cash flow information. The document also discusses business progress, pipeline updates, and corporate developments. It references the filing of a 10-Q quarterly report with the SEC for more detailed financial information. The length of the document (over 13,000 characters) and the inclusion of substantive financial statements and analysis confirm it is a full interim/quarterly financial report rather than a brief earnings release or announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q2 2024
2024-08-07 Chinese
百济神州有限公司2024年半年度主要财务数据公告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2024年半年度主要财务数据公告" which translates to "2024 Half-Year Main Financial Data Announcement." It contains detailed financial data for the half-year period ending June 30, 2024, including revenue, profit, net loss, assets, and equity figures. The document also includes explanations of business performance, financial condition, and risk factors. The data is preliminary and unaudited, prepared according to Chinese accounting standards, and references a related US GAAP unaudited financial performance release. The length of the document (6448 characters) and the presence of substantive financial data and analysis indicate this is a financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). It is not a mere announcement of a report (RPA), nor a full annual report (10-K), nor a simple earnings release (ER) which would be shorter and less detailed. Hence, the classification is IR with high confidence. H1 2024
2024-08-07 Chinese
美股公告：季度报告10-Q表格
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q quarterly report filed with the U.S. Securities and Exchange Commission (SEC) for the period ending June 30, 2024. It includes detailed unaudited financial statements such as consolidated income statements, balance sheets, cash flow statements, and notes to the financial statements. The document also contains management's discussion and analysis of financial conditions and results of operations, risk factors, legal proceedings, and other required disclosures typical of a quarterly report. The presence of the SEC form header "10-Q", the fiscal period dates, and comprehensive financial data confirms this is a quarterly interim report rather than an annual report or other filing type. The document length (15,000 characters) and detailed financial content further support classification as an Interim / Quarterly Report (IR). Q2 2024
2024-08-07 Chinese
港股公告：证券变动月报表
Share Issue/Capital Change Classification · 95% confidence The document is a monthly securities movement report for BeiGene Ltd. as submitted to the Hong Kong Stock Exchange. It details changes in registered capital, issued shares, stock options exercised, and confirmations related to compliance with listing rules. The document includes specific data on share issuance, stock options exercised, and confirmations by the company's executive director. It is a regulatory compliance report related to share capital changes and stock movements, not a financial report, earnings release, or management discussion. It is not an announcement of a report publication but a substantive monthly report on securities changes. This fits the category of Share Issue/Capital Change (SHA) filings, which cover announcements regarding new share issues and capital changes.
2024-08-06 Chinese
港股公告：翌日披露报表
Transaction in Own Shares Classification · 100% confidence The document is a detailed disclosure report about changes in issued shares and treasury shares of a listed company, referencing specific Hong Kong Stock Exchange Listing Rules (Main Board and GEM). It includes data on share issuance, share repurchases, and confirmations of compliance with regulatory requirements. The document is structured as a regulatory disclosure form (FF305) for share capital changes and share repurchases, with no financial statements or earnings data. It is not an announcement of a report publication but the actual disclosure itself. This matches the definition of a Transaction in Own Shares (POS) filing, which covers company buybacks or sales of its own shares.
2024-08-01 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 95% confidence The document is a detailed disclosure report about changes in issued shares and treasury shares, including share issuance under equity plans and share repurchases, as required by the Hong Kong Stock Exchange Listing Rules (Main Board and GEM). It includes specific share counts, dates, prices, and confirmations of compliance with listing rules. The document is not an announcement of a report publication but the actual disclosure itself. It is not a full annual or interim report, nor an earnings release or management discussion. It is a regulatory disclosure specifically about share capital changes and share repurchases. This fits the definition of a Share Issue/Capital Change (SHA) filing, which covers announcements regarding new share issues, stock splits, or other capital changes. The document length is 4052 characters, which is sufficient for a substantive disclosure rather than a brief announcement. Therefore, the correct classification is SHA with high confidence.
2024-07-31 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.